Scarica l'app Stockscreener
30.06
0.17%
0.05
Dopo l'orario di chiusura:
30.06
Precedente Chiudi:
$30.01
Aprire:
$30.06
Volume 24 ore:
190.39K
Relative Volume:
0.94
Capitalizzazione di mercato:
$567.21M
Reddito:
-
Utile/perdita netta:
$-83.49M
Rapporto P/E:
-6.7444
EPS:
-4.457
Flusso di cassa netto:
$-60.29M
1 W Prestazione:
+7.17%
1M Prestazione:
+7.78%
6M Prestazione:
+67.65%
1 anno Prestazione:
+46.56%
Intervallo 1D:
$29.14
$31.20
Intervallo di 1 settimana:
$27.30
$31.20
Portata 52W:
$14.38
$36.03
Tectonic Therapeutic Inc Stock (TECX) Company Profile
Nome
Tectonic Therapeutic Inc
Settore
Industria
Telefono
(339) 666-3320
Indirizzo
490 ARSENAL WAY, WATERTOWN
Compare TECX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TECX
Tectonic Therapeutic Inc
|
30.06 | 554.57M | 0 | -83.49M | -60.29M | -4.457 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tectonic Therapeutic Inc Stock (TECX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | Stifel | Buy |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-09-03 | Iniziato | Oppenheimer | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-04-21 | Iniziato | Mizuho | Outperform |
| 2024-11-20 | Iniziato | Raymond James | Outperform |
| 2024-08-22 | Iniziato | Wells Fargo | Overweight |
| 2024-06-26 | Iniziato | Piper Sandler | Overweight |
| 2024-06-24 | Iniziato | TD Cowen | Buy |
| 2023-12-18 | Downgrade | Mizuho | Buy → Neutral |
| 2022-01-05 | Downgrade | BTIG Research | Buy → Neutral |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-06-27 | Iniziato | Mizuho | Buy |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2018-10-10 | Iniziato | Guggenheim | Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-17 | Iniziato | H.C. Wainwright | Buy |
| 2018-07-16 | Iniziato | Wedbush | Outperform |
| 2018-07-16 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Tectonic Therapeutic Inc Borsa (TECX) Ultime notizie
Tectonic Therapeutic (TECX) CFO receives 7,500 performance stock options at $16.80 - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Tectonic Therapeutic (TECX) - The Globe and Mail
Tectonic completes enrollment in TX45 pulmonary hypertension trial - Investing.com UK
Tectonic completes enrollment in TX45 pulmonary hypertension trial By Investing.com - Investing.com Australia
Tectonic Therapeutic Completes Enrollment in Key TX45 Trial - TipRanks
Tectonic Therapeutic (TECX) finishes TX45 Phase 2 APEX enrollment, sets early Q1 2027 data - Stock Titan
Director at Tectonic Therapeutic (TECX) awarded 10,200 options - Stock Titan
Director at Tectonic Therapeutic (TECX) granted 10,200 stock options - Stock Titan
Tectonic Therapeutic (TECX) director receives 10,200 stock options at $28.56 - Stock Titan
Director at Tectonic Therapeutic (TECX) receives 10,200 stock options expiring 2036 - Stock Titan
Tectonic Therapeutic (TECX) awards 20,400 stock options to director - Stock Titan
New Tectonic Therapeutic (TECX) director Jessica Chutter files initial Form 3 - Stock Titan
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients - GlobeNewswire
Tectonic Therapeutic (TECX) Slides 2.61% as Biotech Sector Faces PressureEquity Put Call - newsline.com
TECX: All proposals passed, with directors reelected and auditor ratified; no shareholder questions - TradingView
Tectonic Therapeutic Inc. (TECX) Advances 2.50% as Shares Test Resistance Near $30.59Continuation Pattern Picks - newsline.com
Tectonic Therapeutic (TECX) Posts 2.5% Gain as Biotech Sentiment ImprovesWyckoff Spring - newsline.com
Tectonic Therapeutic Stock Climbs as Broader Market Sinks - Bez Kabli
Tectonic Therapeutic (TECX) Surges 4.65%: Strong Momentum or Technical Resistance Ahead?Triple EMA - The Legal Advocate
Tectonic Therapeutic (TECX) Slides 1.74% as Biotech Sector Headwinds PersistWeak Sell Signals - The Legal Advocate
Tectonic Therapeutic (TECX) Slips 2.14% as Biotech Stock Consolidates Near Key SupportIV Spike - newsline.com
Raymond James upgrades Tectonic Therapeutic (TECX) - MSN
TECX Upgraded by Raymond James -- Price Target Raised to $81.00 - GuruFocus
Tectonic Therapeutic (TECX) Rallies 3.76% as Biotech Momentum Builds – Key Levels to WatchTrend Following Picks - The Legal Advocate
Tectonic Therapeutic Shares Rise After Raymond James Upgrade - Moomoo
TECX Q1 2026 Earnings: Loss Widens but Pipeline Optimism Drives Stock HigherAnalyst Drop Coverage - The Legal Advocate
Raymond James upgrades Tectonic Therapeutics stock rating on pipeline potential - Investing.com Nigeria
Raymond James Upgrades Tectonic Therapeutic to Strong Buy From Outperform, Adjusts PT to $81 From $76 - marketscreener.com
Tectonic Therapeutic (TECX) Gains 2.1% as Stock Approaches Key Resistance at $30.58SuperTrend Flip - Newser
TECX Q1 2026 Earnings: Wider-than-Expected Loss Amid Pipeline Focus; Stock Edges HigherProfitability Analysis - The Legal Advocate
TECX Q1 2026 Earnings: EPS Miss as Pre-Commercial Biotech Advances PipelineElite Trading Signals - Newser
Tectonic Therapeutic (TECX) Edges Lower as Support Levels Come into FocusSocial Trading Insights - Newser
Tectonic Therapeutic (TECX) Slips Slightly as Stock Holds Above Key SupportLeveraged ETF Flow - Newser
Tectonic Therapeutic (TECX) Q1 2026 Results Fall Short — EPS $-1.34, Revenue $N/AGuidance vs Actual - Newser
Tectonic Therapeutics: Currently In A Catalyst Vacuum (NASDAQ:TECX) - Seeking Alpha
LifeSci Capital Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Oppenheimer Sticks to Its Buy Rating for Tectonic Therapeutic (TECX) - The Globe and Mail
Number of shareholders of Tectonic Therapeutic, Inc. – NASDAQ:TECX - TradingView
Tectonic Therapeutic Gains 11%, Insider Trades Reap Benefit - simplywall.st
Tectonic Therapeutic (TECX) Gets a Buy from Wells Fargo - The Globe and Mail
Truist Financial Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Announces Target Price $60 - 富途牛牛
Wells Fargo Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $101 - Moomoo
MSN Money - MSN
Tectonic Therapeutic, Inc. (TECX) Eps Diluted (TTM) - Zacks Investment Research
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tectonic Therapeutic (TECX), Cullinan Management (CGEM) and Siemens Healthineers AG (OtherSEMHF) - The Globe and Mail
Mizuho Securities Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $85 - Moomoo
Piper Sandler Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $76 - Moomoo
Tectonic Therapeutic, Inc. (TECX) Stock Analysis: Unveiling a Remarkable 189.87% Potential Upside - DirectorsTalk Interviews
Tectonic Therapeutic (NASDAQ:TECX) Issues Quarterly Earnings Results, Misses Expectations By $0.18 EPS - MarketBeat
TECTONIC THERAPEUTIC INC (NASDAQ:TECX) Q1 Loss Wider Than Expected, Pipeline Progress Provides Key Catalyst - ChartMill
Tectonic Therapeutic (NASDAQ: TECX) ramps R&D spend as cash tops $236M - Stock Titan
Tectonic Therapeutic Inc Azioni (TECX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tectonic Therapeutic Inc Azioni (TECX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ruddy Marcella K. | Chief Medical Officer |
Apr 01 '26 |
Sale |
31.05 |
1,000 |
31,050 |
68,747 |
| Ruddy Marcella K. | Chief Medical Officer |
Mar 06 '26 |
Sale |
30.00 |
10,000 |
300,000 |
69,747 |
| McNamara Peter | Chief Scientific Officer |
Mar 06 '26 |
Option Exercise |
3.36 |
2,715 |
9,113 |
61,547 |
| McNamara Peter | Chief Scientific Officer |
Mar 06 '26 |
Sale |
30.17 |
6,262 |
188,935 |
55,285 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):